Mont-Saint-Guibert, Belgium – October 20, 2022 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a pioneering medical technology company dedicated to developing innovative solutions for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 15-17, 2022, at The Waldorf Hilton in London.
During the event, Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update during a fireside chat on Thursday, November 17, 2022, at 10:25 am GMT. The presentation will be accessible via a webcast available on the Events section of Nyxoah’s Investor Relations website. Additionally, the Company will be holding one-on-one meetings with institutional investors attending the conference.

Investors can also find Nyxoah’s updated Investor Presentation in the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah: Nyxoah specializes in developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA). The company’s flagship product, the Genio® system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to address OSA, the most common sleep-related breathing disorder, which poses significant health risks, including increased mortality and cardiovascular issues.

After successfully completing the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah has successfully executed two IPOs: one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021. Following the favorable results from the BETTER SLEEP study, Nyxoah obtained CE mark approval for expanding its therapeutic indications to include Complete Concentric Collapse (CCC) patients, a demographic currently excluded from competitors’ therapies. The Company is also conducting the DREAM IDE pivotal study in pursuit of FDA and U.S. commercialization approval.